GBR-13119
GBR-13119[edit | edit source]
GBR-13119 is a chemical compound that acts as a potent and selective dopamine reuptake inhibitor. It is part of the piperazine class of drugs and has been studied for its potential use in the treatment of various neurological and psychiatric disorders.
Pharmacology[edit | edit source]
GBR-13119 functions primarily by inhibiting the reuptake of dopamine in the brain. This action increases the concentration of dopamine in the synaptic cleft, thereby enhancing dopaminergic neurotransmission. The compound binds to the dopamine transporter (DAT) with high affinity, preventing the reabsorption of dopamine into the presynaptic neuron.
Mechanism of Action[edit | edit source]
The mechanism of action of GBR-13119 involves its interaction with the dopamine transporter (DAT). By binding to DAT, GBR-13119 blocks the reuptake of dopamine, leading to increased levels of dopamine in the synaptic cleft. This results in prolonged dopaminergic signaling, which can affect various physiological and behavioral processes.
Potential Therapeutic Uses[edit | edit source]
GBR-13119 has been investigated for its potential therapeutic applications in several conditions, including:
- Attention deficit hyperactivity disorder (ADHD)
- Parkinson's disease
- Depression
- Substance use disorders
Research and Development[edit | edit source]
Research on GBR-13119 has primarily focused on its pharmacological properties and potential therapeutic benefits. Studies have shown that it can effectively increase dopamine levels in the brain, which may be beneficial in treating disorders characterized by dopamine dysregulation.
Safety and Side Effects[edit | edit source]
As with other dopamine reuptake inhibitors, GBR-13119 may have side effects related to its dopaminergic activity. Potential side effects include:
Related Compounds[edit | edit source]
GBR-13119 is structurally related to other piperazine derivatives, such as GBR-12909 and GBR-12935, which also act as dopamine reuptake inhibitors.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
